Loading
A phase 2 trial of JYP0015 in pancreatic ductal adenocarcinoma and non-small-cell lung cancer, run by Guangzhou JOYO Pharma Co., Ltd, now recruiting.
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS is a phase 2 interventional study registered as NCT06895031 by Guangzhou JOYO Pharma Co., Ltd, with 210 participants planned, started 2025-03-31 and due to reach its primary completion in 2026-03-30. Interventions recorded: JYP0015. Conditions listed: Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares JYP0015, Colorectal cancer.
Shares JYP0015, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/